Monday, Sep 17, 2018 8:00a -
Tuesday, Sep 18, 2018 5:00p
Revere Hotel Boston Common
200 Stuart Street
Boston, MA 02116
Lectures & Conferences
The FDA's approval of the first wave of biosimilars in 2015 cleared the way for manufacturers to make lower-cost versions of expensive biologic drugs, saving patients money and improving access to vital medications. There is a significant market opportunity ahead for biosimilar developers if they can figure out a strategic plan to enhance the commercialization of the biosimilar.
Studies show that by 2020, leading biologic medicines worth more than $80 billion global annual sales will lose their patent protections, and biosimilars make up the largest area of potential growth in the biotech sector. But with great rewards, there are also significant risks to consider. In contrast to Europe, this is still an uncharted territory for the U.S. market, and barriers to market access are not as low as they seem to be. From FDA approval to pricing and marketing strategies, there are risks and financial uncertainties. Therefore, the industry needs to know how to address those challenges and optimize the biosimilar launch process expertly.
Whether you are exploring your chances of tapping into the competitive biosimilars marketplace or are an expert in the field, the Biosimilar Market Access and Commercialization Strategies Summit will provide detailed presentations, intensive case studies and collaborative panel discussions relevant to your interests.
Our talented faculty will address everything from navigating evolving regulations, analyzing optimal pricing models, accelerating market access strategies, and executing strategic decisions to mitigate risk and build for commercial success. Also designated lunches and networking breaks will enhance the exchange of knowledge and foster future business partnerships.
Conference Only - Early Bird Pricing before August 3, 2018: USD 1895.0,
Conference Only - Standard Pricing after August 3, 2018: USD 2095.0,
Conference Only - Onsite Pricing: USD 2295.0
Speakers: Jay Brown, Sr. Director Outpatient Pharmacy Services, NOVANT HEALTH, INC, Niraj Chhaya, Risk Management, Biosimilars, BOEHRINGER INGELHEIM LIMITED, Mona Chitre, Vice President of Pharmacy, EXCELLUS BLUECROSS BLUESHIELD, Christopher Colburn, Director Federal Accounts - Biosimilar Products, PFIZER INCORPORATED, Ruediger Jankowsky, Managing Director, CINFA BIOTECH, Divya Chadha Manek, Head, Business Development, NIHR, Bruce Leicher, Senior Vice President and General Counsel, MOMENTA PHARMACEUTICALS, Rob Jacobson, Executive Director, AMGEN, Sarfaraz Niazi, Adjunct Professor, Department of Biopharmaceutical Sciences, UNIVERSITY OF ILLINOIS AT CHICAGO, COLLEGE OF PHARMACY, Joanna Brougher, Adjunct Professor, CORNELL LAW SCHOOL, Aaron Hakim, Researcher, YALE UNIVERSITY SCHOOL OF MEDICINE, Nacer Hedroug, Associate Director Validation and Tech Transfer, WOCKHARDT LTD., Joseph P. Fuhr, Ph.D., Adjunct Faculty College of Population Health and Professor Emeritus Economics, WIDENER UNIVERSITY